Pharmafile Logo
Pharmafocus logo
Advanced Search

opdivo

Showing 15 posts of 107 posts found.

humacao_exterior

Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016

July 29, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, finance, opdivo

Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps …

News

Shire and BMS secure NICE recommendations for oncology drugs

July 27, 2016
Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …

News

BMS names Fouad Namouni as new oncology development head

July 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo

Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …

Appointment
lab

AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo

July 26, 2016
Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t

AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …

News
opdivo_1

Opdivo to go before EU, US regulators in head and neck cancer

July 19, 2016
Manufacturing and Production, Research and Development EMA, EU, FDA, US, head and neck cancer, opdivo

Bristol-Myers Squibb has announced that its lead oncology drug, Opdivo (nivolumab), is set to go before regulators in the US …

News

Scottish regulators back BMS’ Opdivo for lung cancer

July 13, 2016
Research and Development, Sales and Marketing Bristol-Myers Sqibb, NICE, Scottish Medicines Consortium, lung cancer, opdivo, regulation

Bristol-Myers Squibb (NYSE: BMY) said the Scottish Medicines Consortium (SMC) has recommended cancer immunotherapy Opdivo (nivolumab) to treat advanced squamous …

News

Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation

UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …

News

Bristol-Myers Squibb’s Opdivo gets US FDA breakthrough therapy designation for advanced bladder cancer

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, bladder cancer, opdivo, regulation

Bristol-Myers Squibb (NYSE:BMY) said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to its immunotherapy Opdivo for the …

News

Nice backs BMS’ combination immunotherapy Opdivo, Yervoy to treat skin cancer

June 17, 2016
Medical Communications, Research and Development, Sales and Marketing BMS, NICE, oncology, opdivo, regulation, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …

News
opdivo_1

Bristol-Myers Squibb presents Opdivo data at ASCO

June 6, 2016
Research and Development, Sales and Marketing ASCO, Bristol-Myers Squibb, opdivo

Bristol-Myers Squibb (NYSE: BMY) has presented a wide range of results on Opdivo (nivolumab) in a range of oncology indications …

News
bmslogo

BMS says Phase III trials for Opdivo show improved overall survival in lung cancer

May 19, 2016
Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo

Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …

News
opdivo_1

Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma

May 18, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo

Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …

News
opdivo_1_1

Focus: Bristol-Myers Squibb’s wonder drug – Opdivo

April 20, 2016
Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales

By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …

Feature
bms_building_uk

Bristol-Myers Squibb’s Opdivo shows positive results in early stage trials for advanced skin cancer

April 19, 2016
Manufacturing and Production, Research and Development Bristol-Myers Squibb, drug trial, immuno-therapy, oncology, opdivo

New data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat advanced melanoma showed overall survival of five years in 34% patients, …

News
opdivo_1

Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials

April 19, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous

Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023